The CHEK2-associated breast cancer risk of 20–30% lifetime is not generally high enough to warrant consideration of risk-reducing bilateral mastectomy, but heightened surveillance with additional annual breast MRI is recommended (75). The gene discussed is CHEK2; the disease is breast carcinoma.